Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

BACKGROUND: Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations are common in acute myeloid leukemia (AML) and are associated with rapid relapse and short survival. In relapsed/refractory (R/R) AML, the clinical benefit of FLT3 inhibitors has been limited by rapid generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Perl, Alexander E., Altman, Jessica K., Cortes, Jorge, Smith, Catherine, Litzow, Mark, Baer, Maria R., Claxton, David, Erba, Harry P., Gill, Stan, Goldberg, Stuart, Jurcic, Joseph G., Larson, Richard A., Liu, Chaofeng, Ritchie, Ellen, Schiller, Gary, Spira, Alexander I., Strickland, Stephen A., Tibes, Raoul, Ustun, Celalettin, Wang, Eunice S., Stuart, Robert, Röllig, Christoph, Neubauer, Andreas, Martinelli, Giovanni, Bahceci, Erkut, Levis, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572576/
https://www.ncbi.nlm.nih.gov/pubmed/28645776
http://dx.doi.org/10.1016/S1470-2045(17)30416-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572576/
https://www.ncbi.nlm.nih.gov/pubmed/28645776
http://dx.doi.org/10.1016/S1470-2045(17)30416-3

Ejemplares similares